Skip to Main Content

Yet another country has begun battling with Vertex Pharmaceuticals (VRTX) over its cystic fibrosis medicines. In a new report, an independent Canadian advisory group has rejected the use of the Orkambi treatment over questions about both its cost and clinical effectiveness.

In reaching its conclusion, the Canadian Agency for Drugs and Technologies in Health cited uncertainty over clinical trials measuring the extent to which the drug improved patient health; a lack of studies gauging the effect Orkambi has on a need for lung transplants or survival; and no statistically significant improvements in health-related quality of life based on patient questionnaires, among other things.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.